News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
U.S. Clears GlaxoSmithKline Drug For Preventing Influenza
March 29, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON (Reuters) - GlaxoSmithKline Plc's prescription flu treatment Relenza has won U.S. approval for preventing influenza in adults and children ages 5 and older, regulators said on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
GSK
MORE ON THIS TOPIC
Manufacturing
HHS clears compounding pharmacies to manufacture 6 unapproved peptides
October 29, 2026
·
2 min read
·
Nick Paul Taylor
Insights
Stability, speed and strategy: Inside Australia’s early‑stage edge
October 29, 2026
·
1 min read
·
Jennifer C. Smith-Parker
FDA
New FDA draft guidance doubles down on expediting approvals of personalized gene therapies
October 28, 2026
·
4 min read
·
Heather McKenzie
Opinion
Biotechs going to market alone must learn to go global
October 28, 2026
·
3 min read
·
Paul Bridges
